Saniona: Kv7 epilepsy compound selected to candidate selection phase - Redeye

Redeye endorses today’s news that Saniona has initiated the candidate selection phase for “a proprietary subtype selective frontrunner molecule from the Kv7 lead optimization program”, indicating a swift process for the program that further positions Saniona with a strong pipeline within epilepsy. We will discuss this further this Thursday (Life Science Day) and in our Q3 update later in November.

Länk till analysen i sin helhet: https://www.redeye.se/research/962042/saniona-kv7-epilepsy-compound-selected-to-candidate-selection-phase?utm_source=finwire&utm_medium=RSS